Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Hasui, Y. Osada (1997)
Urokinase-type plasminogen activator and its receptor in bladder cancer.Journal of the National Cancer Institute, 89 10
Philip Wakefield, W. James, C. Samlaska, M. Meltzer (1991)
Tumor necrosis factor.Journal of the American Academy of Dermatology, 24 5 Pt 1
C. Belda-Iniesta, R. Perona, J. Carpeño, P. Cejas, E. Casado, C. Manguán-García, I. Cáceres, I. Sánchez-Pérez, F. Andreu, Javier Ferreira, A. Aguilera, J. Peña, Elia Perez-Sánchez, R. Madero, J. Feliu, M. Sereno, M. González-Barón (2007)
Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cellsCancer Biology & Therapy, 6
R. Bhuvaneswari, Y. Gan, K. Soo, M. Olivo (2009)
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor responseMolecular Cancer, 8
J. Ku, W. Choi, C. Kwak, Hyeon-Hoe Kim (2011)
Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract.Urologic oncology, 29 4
石川 博一 (2007)
癌性胸膜炎におけるurokinase-type plasminogen activator (u-PA)に関する検討
K. Blackwell, P. Gascón, G. Sigounas, L. Jolliffe (2004)
rHuEPO and improved treatment outcomes: potential modes of action.The oncologist, 9 Suppl 5
M. Stern, Jie Lin, J. Figueroa, K. Kelsey, A. Kiltie, Jian-Min Yuan, G. Matullo, T. Fletcher, S. Benhamou, S. Benhamou, Jack Taylor, D. Placidi, Zuo‐Feng Zhang, Gunnar Steineck, Gunnar Steineck, N. Rothman, M. Kogevinas, D. Silverman, N. Malats, S. Chanock, Xifeng Wu, M. Karagas, A. Andrew, H. Nelson, D. Bishop, Chung Sei, A. Choudhury, J. Barrett, F. Elliot, Román Corral, A. Joshi, M. Gago-Domínguez, V. Cortessis, Y. Xiang, Yuxue Gao, P. Vineis, C. Sacerdote, S. Guarrera, S. Polidoro, A. Allione, E. Gurzău, K. Koppová, Rajiv Kumar, P. Rudnai, S. Porru, A. Carta, M. Campagna, C. Arici, S. Park, M. García-Closas (2009)
Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer.Cancer research, 69 17
(2009)
matched cancerous tissues
(2007)
Effect of gas phase
(2009)
Erythropoietin protects
F. Egerod, Annette Bartels, Niels Fristrup, M. Borre, T. Ørntoft, M. Oleksiewicz, N. Brünner, L. Dyrskjøt (2009)
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progressionBMC Cancer, 9
L. Adam, Meng Zhong, W. Choi, W. Qi, M. Nicoloso, Ameeta Arora, G. Calin, Hua Wang, A. Siefker-Radtke, D. McConkey, M. Bar‐eli, C. Dinney (2009)
miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor TherapyClinical Cancer Research, 15
H. Ozen (1998)
Bladder cancer.Current opinion in oncology, 10 3
Dhungana Sandra, M. Radha, M. Harishkumar, Nakajima Yuichi, Omura Sayuri, Maruyama Masugi (2010)
Downregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 by grape seed proanthocyanidin extract.Phytomedicine : international journal of phytotherapy and phytopharmacology, 17 1
(2003)
Dexamethasone-induced differentiation of pancreatic AR42J cell involves p21 and MAP kinase pathway
Katarzyna Oszajca, M. Bieniasz, George Brown, M. Swiatkowska, J. Bartkowiak, J. Szemraj (2008)
Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.Biochemistry and cell biology = Biochimie et biologie cellulaire, 86 6
W. Eum, M. Li, Gye Sin, Soo‐Young Choi, Jae-Bong Park, Jae Lee, H. Kwon (2003)
Dexamethasone-induced differentiation of pancreatic AR42J cell involves p21(waf1/cip1)and MAP kinase pathwayExperimental & Molecular Medicine, 35
R. Madonna, H. Shelat, Q. Xue, J. Willerson, R. Caterina, Y. Geng (2009)
Erythropoietin protects myocardin-expressing cardiac stem cells against cytotoxicity of tumor necrosis factor-alpha.Experimental cell research, 315 17
P. Span, J. Witjes, N. Grebenchtchikov, A. Geurts-Moespot, P. Moonen, T. Aalders, J. Vriesema, L. Kiemeney, J. Schalken, F. Sweep (2008)
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissuesBJU International, 102
T. Gotanda, M. Haraguchi, T. Tachiwada, R. Shinkura, C. Koriyama, S. Akiba, M. Kawahara, K. Nishiyama, T. Sumizawa, T. Furukawa, H. Mimata, Y. Nomura, S. Akiyama, M. Nakagawa (2006)
Molecular basis for the involvement of thymidine phosphorylase in cancer invasion.International journal of molecular medicine, 17 6
(2008)
its receptor in bladder cancer
How-Wen Ko, Y. Tsai, Chih-Teng Yu, Chun-Yao Huang, Chih-Hung Chen (2008)
Good response to gefitinib for lung adenocarcinoma with hyperamylasemia: a case report.Chang Gung medical journal, 31 6
M. Greabu, M. Battino, A. Totan, M. Mohora, N. Mitrea, C. Totan, T. Spînu, A. Didilescu (2007)
Effect of gas phase and particulate phase of cigarette smoke on salivary antioxidants. What can be the role of vitamin C and pyridoxine?Pharmacological reports : PR, 59 5
Bladder and upper urinary tract (UUT; pelvic and/or ureteral) cancers were studied in a total of 118 Japanese patients using serum amylase to clarify their prognosis and treatment. Among 114 patients with urothelial carcinoma (UC), 99, 10, and five had bladder UC, bladder-UUT-UC, and UUT-UC alone, respectively. Three had bladder squamous cell carcinoma, and one had undifferentiated bladder carcinoma. During the 3 years of this study (2007–2009), 35 (30%) patients received radical cystectomy at a mean age of 72 ± 8 years old, of which 23 (66%) demonstrated muscle invasion (pT2≤). Five (4%) patients showed post-operative hyperamylasemia with serum amylase levels of 1,353–2,986 IU/l. Except for one case of UUT-UC with mild operative bleeding, in four other bladder UC cases, severe fibrinolytic bleeding was observed, and their continuing bleeding was accompanied by a post-operative elevated serum amylase. One patient with a serum amylase level of 2,986 IU/l showed severe post-operative pelvic bleeding and severely necrotic UC recurrence involving prostate and urethral remnants and died of intestinal perforation about 1 year post-cystectomy. Serum amylase was secreted from bladder cancers in parallel with the amount of tissue-type plasminogen activator (t-PA), although serum amylase secreted maximally a little later than t-PA after serum Ca was returning to normal. Five patients showed brain metastases with a low level of serum amylase, near to normal serum Ca, and high levels of alkaline phosphatase at advanced cancer stages, and another four with hypercoagulation showed cerebral infarction with similar laboratory findings to those of the former five, of which three had severe chronic renal failure. The proteolytic reactions of the urokinase-type PA secreted from bladder cancer caused tissue necrosis, especially in the intestine, resulting in intestinal perforation and remote bone and brain metastases. In the CRF patients, recombinant erythropoietin was effective for treating hypoxia.
Comparative Clinical Pathology – Springer Journals
Published: Mar 27, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.